Gluxit Trio 10/100/1000 Tablet ER is a fixed-dose combination medication containing Dapagliflozin 10 mg, Metformin 1000 mg, and Sitagliptin 100 mg, formulated as an extended-release tablet for the management of type 2 diabetes mellitus. This combination targets multiple pathophysiological defects in type 2 diabetes by utilizing complementary mechanisms of action. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, promotes renal glucose excretion, thereby reducing plasma glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone levels, resulting in increased insulin release and decreased glucagon secretion in a glucose-dependent manner. The extended-release formulation allows for once-daily dosing, improving patient adherence and maintaining stable plasma drug concentrations. Gluxit Trio is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes inadequately controlled on monotherapy or dual therapy. Caution is advised in patients with renal impairment, hepatic dysfunction, or risk factors for lactic acidosis. Regular monitoring of renal function, glycemic parameters, and potential adverse effects such as urinary tract infections or gastrointestinal disturbances is recommended during therapy.